Bemcentinib as monotherapy and in combination with low-dose cytarabine in acute myeloid leukemia patients unfit for intensive chemotherapy: a phase 1b/2a trial.
Saved in:
| Title: | Bemcentinib as monotherapy and in combination with low-dose cytarabine in acute myeloid leukemia patients unfit for intensive chemotherapy: a phase 1b/2a trial. |
|---|---|
| Authors: | Loges S; German-Cancer-Research-Center-(DKFZ)-Hector Cancer Institute, University Medical Center Mannheim, Mannheim, Germany. s.loges@dkfz-heidelberg.de.; Division of Personalized Medical Oncology (A420), German Cancer Research Center (DKFZ), Heidelberg, Germany. s.loges@dkfz-heidelberg.de.; Department of Personalized Oncology, University Hospital Mannheim, and Medical Faculty Mannheim, University of Heidelberg, Mannheim, Germany. s.loges@dkfz-heidelberg.de., Heuser M; Hematology, Hemostasis, Oncology and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany.; Comprehensive Cancer Center Niedersachsen, Hannover Medical School, Hannover, Germany., Chromik J; University Hospital Frankfurt, Frankfurt, Germany., Sutamtewagul G; University of Iowa Hospitals and Clinics, Iowa City, IA, US., Kapp-Schwoerer S; University Hospital of Ulm, Ulm, Germany., Crugnola M; University of Parma, Parma, Italy., Di Renzo N; Haematology and Stem Cell Transplantation Unit, Vito Fazzi Hospital, Lecce, Italy., Lemoli R; Department of Internal medicine (DIMI), University of Genoa, Genoa, Italy.; IRCCS-San Martino Hospital, Genoa, Italy., Mattei D; Azienda Sanitaria Ospedaliera (ASO) Santa Croce e Carle, Cuneo, Italy., Fiedler W; University Medical Center Hamburg-Eppendorf, Hamburg, Germany., Alvarado-Valero Y; The University of Texas M.D. Anderson Cancer Center, Houston, TX, US., Ben-Batalla I; German-Cancer-Research-Center-(DKFZ)-Hector Cancer Institute, University Medical Center Mannheim, Mannheim, Germany.; Division of Personalized Medical Oncology (A420), German Cancer Research Center (DKFZ), Heidelberg, Germany.; Department of Personalized Oncology, University Hospital Mannheim, and Medical Faculty Mannheim, University of Heidelberg, Mannheim, Germany., Waizenegger J; German-Cancer-Research-Center-(DKFZ)-Hector Cancer Institute, University Medical Center Mannheim, Mannheim, Germany.; Division of Personalized Medical Oncology (A420), German Cancer Research Center (DKFZ), Heidelberg, Germany.; Department of Personalized Oncology, University Hospital Mannheim, and Medical Faculty Mannheim, University of Heidelberg, Mannheim, Germany., Rieckmann LM; German-Cancer-Research-Center-(DKFZ)-Hector Cancer Institute, University Medical Center Mannheim, Mannheim, Germany.; Division of Personalized Medical Oncology (A420), German Cancer Research Center (DKFZ), Heidelberg, Germany.; Department of Personalized Oncology, University Hospital Mannheim, and Medical Faculty Mannheim, University of Heidelberg, Mannheim, Germany., Janning M; German-Cancer-Research-Center-(DKFZ)-Hector Cancer Institute, University Medical Center Mannheim, Mannheim, Germany.; Division of Personalized Medical Oncology (A420), German Cancer Research Center (DKFZ), Heidelberg, Germany.; Department of Personalized Oncology, University Hospital Mannheim, and Medical Faculty Mannheim, University of Heidelberg, Mannheim, Germany., Collienne M; German-Cancer-Research-Center-(DKFZ)-Hector Cancer Institute, University Medical Center Mannheim, Mannheim, Germany.; Division of Personalized Medical Oncology (A420), German Cancer Research Center (DKFZ), Heidelberg, Germany.; Department of Personalized Oncology, University Hospital Mannheim, and Medical Faculty Mannheim, University of Heidelberg, Mannheim, Germany., Imbusch CD; Division of Applied Bioinformatics (B330), German Cancer Research Center (DKFZ), Heidelberg, Germany.; Institute of Immunology, University Medical Center Mainz, Mainz, Germany and Research Center for Immunotherapy (FZI), Mainz, Germany., Beumer N; German-Cancer-Research-Center-(DKFZ)-Hector Cancer Institute, University Medical Center Mannheim, Mannheim, Germany.; Division of Personalized Medical Oncology (A420), German Cancer Research Center (DKFZ), Heidelberg, Germany.; Department of Personalized Oncology, University Hospital Mannheim, and Medical Faculty Mannheim, University of Heidelberg, Mannheim, Germany.; Division of Applied Bioinformatics (B330), German Cancer Research Center (DKFZ), Heidelberg, Germany.; Faculty of Biosciences, Heidelberg University, Heidelberg, Germany.; Institute of Immunology, University Medical Center Mainz, Mainz, Germany and Research Center for Immunotherapy (FZI), Mainz, Germany., Micklem D; BerGenBio ASA, Bergen, Norway., H Nilsson L; BerGenBio ASA, Bergen, Norway., Madeleine N; BerGenBio ASA, Bergen, Norway., McCracken N; BerGenBio Ltd, Oxford, UK., Oliva C; BerGenBio Ltd, Oxford, UK., Gorcea-Carson C; BerGenBio Ltd, Oxford, UK., Gjertsen BT; Haukeland University Hospital, Bergen, Norway, & Centre for Cancer Biomarkers (CCBIO), Department of Clinical Science, University of Bergen, Bergen, Norway. |
| Source: | Nature communications [Nat Commun] 2025 Mar 23; Vol. 16 (1), pp. 2846. Date of Electronic Publication: 2025 Mar 23. |
| Publication Type: | Journal Article; Clinical Trial, Phase I; Clinical Trial, Phase II; Multicenter Study |
| Journal Info: | Publisher: Nature Pub. Group Country of Publication: England NLM ID: 101528555 Publication Model: Electronic Cited Medium: Internet ISSN: 2041-1723 (Electronic) Linking ISSN: 20411723 NLM ISO Abbreviation: Nat Commun Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| FullText | Links: – Type: pdflink Text: Availability: 1 |
|---|---|
| Header | DbId: mdl DbLabel: MEDLINE Ultimate An: 40122885 AccessLevel: 2 PubType: Academic Journal PubTypeId: academicJournal PreciseRelevancyScore: 0 |
| IllustrationInfo | |
| Items | – Name: Title Label: Title Group: Ti Data: Bemcentinib as monotherapy and in combination with low-dose cytarabine in acute myeloid leukemia patients unfit for intensive chemotherapy: a phase 1b/2a trial. – Name: Author Label: Authors Group: Au Data: <searchLink fieldCode="AU" term="%22Loges+S%22">Loges S</searchLink>; German-Cancer-Research-Center-(DKFZ)-Hector Cancer Institute, University Medical Center Mannheim, Mannheim, Germany. s.loges@dkfz-heidelberg.de.; Division of Personalized Medical Oncology (A420), German Cancer Research Center (DKFZ), Heidelberg, Germany. s.loges@dkfz-heidelberg.de.; Department of Personalized Oncology, University Hospital Mannheim, and Medical Faculty Mannheim, University of Heidelberg, Mannheim, Germany. s.loges@dkfz-heidelberg.de.<br /><searchLink fieldCode="AU" term="%22Heuser+M%22">Heuser M</searchLink>; Hematology, Hemostasis, Oncology and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany.; Comprehensive Cancer Center Niedersachsen, Hannover Medical School, Hannover, Germany.<br /><searchLink fieldCode="AU" term="%22Chromik+J%22">Chromik J</searchLink>; University Hospital Frankfurt, Frankfurt, Germany.<br /><searchLink fieldCode="AU" term="%22Sutamtewagul+G%22">Sutamtewagul G</searchLink>; University of Iowa Hospitals and Clinics, Iowa City, IA, US.<br /><searchLink fieldCode="AU" term="%22Kapp-Schwoerer+S%22">Kapp-Schwoerer S</searchLink>; University Hospital of Ulm, Ulm, Germany.<br /><searchLink fieldCode="AU" term="%22Crugnola+M%22">Crugnola M</searchLink>; University of Parma, Parma, Italy.<br /><searchLink fieldCode="AU" term="%22Di+Renzo+N%22">Di Renzo N</searchLink>; Haematology and Stem Cell Transplantation Unit, Vito Fazzi Hospital, Lecce, Italy.<br /><searchLink fieldCode="AU" term="%22Lemoli+R%22">Lemoli R</searchLink>; Department of Internal medicine (DIMI), University of Genoa, Genoa, Italy.; IRCCS-San Martino Hospital, Genoa, Italy.<br /><searchLink fieldCode="AU" term="%22Mattei+D%22">Mattei D</searchLink>; Azienda Sanitaria Ospedaliera (ASO) Santa Croce e Carle, Cuneo, Italy.<br /><searchLink fieldCode="AU" term="%22Fiedler+W%22">Fiedler W</searchLink>; University Medical Center Hamburg-Eppendorf, Hamburg, Germany.<br /><searchLink fieldCode="AU" term="%22Alvarado-Valero+Y%22">Alvarado-Valero Y</searchLink>; The University of Texas M.D. Anderson Cancer Center, Houston, TX, US.<br /><searchLink fieldCode="AU" term="%22Ben-Batalla+I%22">Ben-Batalla I</searchLink>; German-Cancer-Research-Center-(DKFZ)-Hector Cancer Institute, University Medical Center Mannheim, Mannheim, Germany.; Division of Personalized Medical Oncology (A420), German Cancer Research Center (DKFZ), Heidelberg, Germany.; Department of Personalized Oncology, University Hospital Mannheim, and Medical Faculty Mannheim, University of Heidelberg, Mannheim, Germany.<br /><searchLink fieldCode="AU" term="%22Waizenegger+J%22">Waizenegger J</searchLink>; German-Cancer-Research-Center-(DKFZ)-Hector Cancer Institute, University Medical Center Mannheim, Mannheim, Germany.; Division of Personalized Medical Oncology (A420), German Cancer Research Center (DKFZ), Heidelberg, Germany.; Department of Personalized Oncology, University Hospital Mannheim, and Medical Faculty Mannheim, University of Heidelberg, Mannheim, Germany.<br /><searchLink fieldCode="AU" term="%22Rieckmann+LM%22">Rieckmann LM</searchLink>; German-Cancer-Research-Center-(DKFZ)-Hector Cancer Institute, University Medical Center Mannheim, Mannheim, Germany.; Division of Personalized Medical Oncology (A420), German Cancer Research Center (DKFZ), Heidelberg, Germany.; Department of Personalized Oncology, University Hospital Mannheim, and Medical Faculty Mannheim, University of Heidelberg, Mannheim, Germany.<br /><searchLink fieldCode="AU" term="%22Janning+M%22">Janning M</searchLink>; German-Cancer-Research-Center-(DKFZ)-Hector Cancer Institute, University Medical Center Mannheim, Mannheim, Germany.; Division of Personalized Medical Oncology (A420), German Cancer Research Center (DKFZ), Heidelberg, Germany.; Department of Personalized Oncology, University Hospital Mannheim, and Medical Faculty Mannheim, University of Heidelberg, Mannheim, Germany.<br /><searchLink fieldCode="AU" term="%22Collienne+M%22">Collienne M</searchLink>; German-Cancer-Research-Center-(DKFZ)-Hector Cancer Institute, University Medical Center Mannheim, Mannheim, Germany.; Division of Personalized Medical Oncology (A420), German Cancer Research Center (DKFZ), Heidelberg, Germany.; Department of Personalized Oncology, University Hospital Mannheim, and Medical Faculty Mannheim, University of Heidelberg, Mannheim, Germany.<br /><searchLink fieldCode="AU" term="%22Imbusch+CD%22">Imbusch CD</searchLink>; Division of Applied Bioinformatics (B330), German Cancer Research Center (DKFZ), Heidelberg, Germany.; Institute of Immunology, University Medical Center Mainz, Mainz, Germany and Research Center for Immunotherapy (FZI), Mainz, Germany.<br /><searchLink fieldCode="AU" term="%22Beumer+N%22">Beumer N</searchLink>; German-Cancer-Research-Center-(DKFZ)-Hector Cancer Institute, University Medical Center Mannheim, Mannheim, Germany.; Division of Personalized Medical Oncology (A420), German Cancer Research Center (DKFZ), Heidelberg, Germany.; Department of Personalized Oncology, University Hospital Mannheim, and Medical Faculty Mannheim, University of Heidelberg, Mannheim, Germany.; Division of Applied Bioinformatics (B330), German Cancer Research Center (DKFZ), Heidelberg, Germany.; Faculty of Biosciences, Heidelberg University, Heidelberg, Germany.; Institute of Immunology, University Medical Center Mainz, Mainz, Germany and Research Center for Immunotherapy (FZI), Mainz, Germany.<br /><searchLink fieldCode="AU" term="%22Micklem+D%22">Micklem D</searchLink>; BerGenBio ASA, Bergen, Norway.<br /><searchLink fieldCode="AU" term="%22H+Nilsson+L%22">H Nilsson L</searchLink>; BerGenBio ASA, Bergen, Norway.<br /><searchLink fieldCode="AU" term="%22Madeleine+N%22">Madeleine N</searchLink>; BerGenBio ASA, Bergen, Norway.<br /><searchLink fieldCode="AU" term="%22McCracken+N%22">McCracken N</searchLink>; BerGenBio Ltd, Oxford, UK.<br /><searchLink fieldCode="AU" term="%22Oliva+C%22">Oliva C</searchLink>; BerGenBio Ltd, Oxford, UK.<br /><searchLink fieldCode="AU" term="%22Gorcea-Carson+C%22">Gorcea-Carson C</searchLink>; BerGenBio Ltd, Oxford, UK.<br /><searchLink fieldCode="AU" term="%22Gjertsen+BT%22">Gjertsen BT</searchLink>; Haukeland University Hospital, Bergen, Norway, & Centre for Cancer Biomarkers (CCBIO), Department of Clinical Science, University of Bergen, Bergen, Norway. – Name: TitleSource Label: Source Group: Src Data: <searchLink fieldCode="JN" term="%22101528555%22">Nature communications</searchLink> [Nat Commun] 2025 Mar 23; Vol. 16 (1), pp. 2846. <i>Date of Electronic Publication: </i>2025 Mar 23. – Name: TypePub Label: Publication Type Group: TypPub Data: Journal Article; Clinical Trial, Phase I; Clinical Trial, Phase II; Multicenter Study – Name: TitleSource Label: Journal Info Group: Src Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Nature+Pub%2E+Group%22">Nature Pub. Group </searchLink><i>Country of Publication: </i>England <i>NLM ID: </i>101528555 <i>Publication Model: </i>Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>2041-1723 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2220411723%22">20411723 </searchLink><i>NLM ISO Abbreviation: </i>Nat Commun <i>Subsets: </i>MEDLINE |
| PLink | https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=40122885 |
| RecordInfo | BibRecord: BibEntity: Identifiers: – Type: doi Value: 10.1038/s41467-025-58179-6 Languages: – Code: eng Text: English PhysicalDescription: Pagination: StartPage: 2846 Titles: – TitleFull: Bemcentinib as monotherapy and in combination with low-dose cytarabine in acute myeloid leukemia patients unfit for intensive chemotherapy: a phase 1b/2a trial. Type: main BibRelationships: HasContributorRelationships: – PersonEntity: Name: NameFull: Loges S – PersonEntity: Name: NameFull: Heuser M – PersonEntity: Name: NameFull: Chromik J – PersonEntity: Name: NameFull: Sutamtewagul G – PersonEntity: Name: NameFull: Kapp-Schwoerer S – PersonEntity: Name: NameFull: Crugnola M – PersonEntity: Name: NameFull: Di Renzo N – PersonEntity: Name: NameFull: Lemoli R – PersonEntity: Name: NameFull: Mattei D – PersonEntity: Name: NameFull: Fiedler W – PersonEntity: Name: NameFull: Alvarado-Valero Y – PersonEntity: Name: NameFull: Ben-Batalla I – PersonEntity: Name: NameFull: Waizenegger J – PersonEntity: Name: NameFull: Rieckmann LM – PersonEntity: Name: NameFull: Janning M – PersonEntity: Name: NameFull: Collienne M – PersonEntity: Name: NameFull: Imbusch CD – PersonEntity: Name: NameFull: Beumer N – PersonEntity: Name: NameFull: Micklem D – PersonEntity: Name: NameFull: H Nilsson L – PersonEntity: Name: NameFull: Madeleine N – PersonEntity: Name: NameFull: McCracken N – PersonEntity: Name: NameFull: Oliva C – PersonEntity: Name: NameFull: Gorcea-Carson C – PersonEntity: Name: NameFull: Gjertsen BT IsPartOfRelationships: – BibEntity: Dates: – D: 23 M: 03 Text: 2025 Mar 23 Type: published Y: 2025 Identifiers: – Type: issn-electronic Value: 2041-1723 Numbering: – Type: volume Value: 16 – Type: issue Value: 1 Titles: – TitleFull: Nature communications Type: main |
| ResultId | 1 |
